Very interesting that there is low volume on PRGO. Based on Mylan's drop, the offer is now down to around $190. a share. Seeing as PRGO has been trading between $185-$190 today, there was the opportunity for shareholders to get out at full value. Yet volume was 50% of normal. I'm assuming Mylan will continue to lose value over the next month until the tender offer is made (@ $45 MYL, the offer drops to $178, @ $40, it is $167. Given that it takes 4 years for the deal to be accretive, it may be that MYL & PRGO shareholders would both be best off selling at current prices. Coury is either a genius... or he is one of the most incompetent and unethical executives out there. Seems like he is doing this for himself at the expense of shareholders(TEVA's target price was ~70% above where MYL is trading now) I hope he is a genius, but suspect this is not going to turn out well for shareholders... with years of value wiped out in this endeavor. I bought MYL in single digits and felt it was a great company until the last years histrionics. Probably ought to sell, but am hoping for a shareholder revolt that replaces Coury.
Wow! you are brave. I looked at puts, but they are ridiculously expensive. Can't see what would keep pushing ACI higher, but the way this keeps surging, you could get whacked by margins calls and take a beating. Suspect it will go back down sooner rather than later, but when... and after hitting what level?
Down on heavy volume, but no news. Now the selling has dried up. Doubt this was institutional, because an institution would not dump and drive down the value of their own shares. Feel like this is some rumor driven action... unless some insider leaked something bad. CARA successfully completed their secondary in early august... and no news releases since the 17th, announcing the commencement of phase 2 trials -- good news. I am thinking this is an opportunity, so I'm gonna add to my position here.
Sentiment: Strong Buy
Or it is just a rat, leaving a sinking ship. The run up is simply a bounce on the change... momentary optimism. I have averaged down a few times, and hold these shares as they are merely options now on an unlikely future. Seems like this company is poised for bankruptcy if they can't generate some sales momentum in the next two quarters.
Buffett's basis in IBM is not that high... and he gets good yield. He would get out and take the loss if he thought this was going down. He is not the dummy you think he is. IBM's cloud division is bigger and FASTER growing than Salesforce... their strategic initiative divisions are growing at 25 - 70%. If they were valued like Salesforce, this 20-25% of the company would have a higher market cap than the company does as a whole. This means almost 75% of the company is valued at zero... even though it throws off a lot of cash.
Please provide tangible info to support your claims...
Analysts project revenue growth of 15% and profit growth of 20% over the next year. Earnings estimates are virtually unchanged over the last 3 months. Now trading @ 14x forward earnings.
Do you have some other information, or are you just selling short?
Mylan offer for Perrigo is worth a whopping $5 more than Perrigo is trading at after the meltdown (2.3 Mylan Shares + $75 = $193). Feel like the street actually feels this has a chance of happening. Pathetic. As a Mylan shareholder, I voted NO! Really want to see Robert Coury go. He did a good job for years, but has been a horse's #$%$ this year... destroying value for MYL shareholders and slapping them with a huge tax bill. Really wish I had sold at $70. Think we will see $40 before we see $70 again. Vote no on the PRGO deal which massively dilutes your holdings.
Innis Free is Mylan's proxy solicitor call 877 750 9499 and tell MYL management NO!
Problem with GILD is zero estimated rev and profit growth. Regeneron and Celgene are still growing close to 20%. This market still favors growth over value.
Maybe GILD could take 2 years profit and buy NFLX -- create a more diversified / growth component to their portfolio. Also, watching TV leads to all sorts of health issues that GILD can treat. LOL
IBM's cloud business is bigger than CRM and is growing faster... 50% YOY
They have a number of other strategic and fast growing 20%+ business segments... and the company trades at 9x forward earnings. Yes, revs are dropping as they get rid of high priced, low margin products. IBMs margins have almost doubled over the past 10 years
Not "worrying" about the shorts... just don't believe in shorting. Shorts are traders, not investors, who use lots of leverage, which -- I feel -- leads to real distortions in the markets.
Ignore comment below... was meant for SWKS board... but my computer played tricks on me... still see AMBA moving with the market and profit taking until things stabilize
Is this company in danger of bankruptcy? Can't find their current cash position or statements by management. I owned this for a long time, then, later traded it between 3 and 4 for a while. Came back a couple years later and this is now a $.37 stock. Either this is a great play on a global economic recovery, or a company on the verge of insolvency. Would appreciate insights and direction to supporting info. Thanks and luck to all.
Pretty definitive statement by a LONG who says they are not selling... you sound more like a SHORT... "wolf in sheep's clothing..." I have concerns on current valuation as analysts numbers seem to ignore dilution... still... this looks like a good investment long term... just waiting for revisions to understand "bad" estimates.
I like this stock and have been following for a few months, but am concerned that all the numbers and estimates seem to be off. All analysts have earnings in the mid-high $.30s, but this does not reflect dilution. Earnings came in at $.20 per diluted share... since their valuations are based on undiluted shares, it would seem their earnings per share and P/E numbers are way off. Clearly the company has a bright future, but as the number of shares were almost doubled recently, is this currently overpriced? Feel as if analysts are overlooking the dilution in their estimates.
Do some research. You are looking at trailing P?E. JAZZ earnings this year are estimated at just under $10 and for 2016 @ just under $12... giving them a current P/E of around 20 and aforward P/E of 15-16. In addition they are growing quickly and are currently about 1/15th the size of GILD... this gives them lots of room to grow... or be gobbled up at a premium by one of the big fish. GILD is also a great company (I own it as well), but most of its growth comes from Sovaldi, its hepatitis treatment. Many new drugs are competing in this space, so it is unclear what GILD's share of the market will be and their multiple is on the low side. Still, it would be a lot easier for JAZZ to double in size/market cap than GILD. Also, it appears you based your numbers on the Yahoo! JAZZ overview page. At least look into analyst estimates before giving incorrect info. Good Luck.
Problem as I see it, is that even if sales go up... they won't have enough cash flow to cover costs. They have maybe 2 quarters to sell this dog and recoup something... or somehow get the share price up as they will have to do another round of financing... and the current share price won't support it. In all likelihood this company is headed to bankruptcy. I feel terrible for folks who are heavily invested in this... (and not thrilled for myself as I hold a few thousand shares).
That is what I was thinking. If 20% of sales are coming from specialty products, that makes AA's specialty division half the size of PCP. Valued per the the Buffet deal, that part of AA's business would be worth 16-18 billion... giving the commodity aluminum business a valuation of negative 4-6 billion. AA's balance sheet shows more stockholder equity and tangible assets than PCP, yet AA's market cap is 1/3 of the value of the PCP deal. AA is being held down by low aluminum prices AND the perception that they are no more than an aluminum miner. Specialty business gets no value... yet.